GuidelineHPB : the official journal of the International Hepato Pancreato Biliary Association2015
Hilar cholangiocarcinoma: expert consensus statement.
Guideline in HPB : the official journal of the International Hepato Pancreato Biliary Association, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 166 papers, 14 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
166 citing papers in PubMed, 14 syntheses or guidelines pooled it, 409 citations in OpenAlex.
- Impact of combined vascular resection on short and long-term results following radical surgery for hilar cholangiocarcinoma: evidence from a systematic assessment.World journal of surgical oncology · 2026Pooled it
- Robotic, laparoscopic, and open surgery for perihilar cholangiocarcinoma: a systematic review and direct pairwise meta-analysis.Frontiers in surgery · 2026Pooled it
- Efficacy and safety of preoperative biliary drainage in patients with Hilar Cholangiocarcinoma: a systematic review and meta-analysis.International journal of surgery (London, England) · 2025Pooled it
- Robotic surgery for perihilar cholangiocarcinoma: a concise systematic review.Surgical endoscopy · 2025Pooled it
- Robotic-assisted radical resection versus open surgery for cholangiocarcinoma: a systematic review and meta-analysis.Journal of robotic surgery · 2024Pooled it
- Guidelines for Perioperative Care for Liver Surgery: Enhanced Recovery After Surgery (ERAS) Society Recommendations 2022.World journal of surgery · 2023Pooled it
- Effects of portal vein resection and hepatic artery resection on long-term survival in Klatskin tumor: a meta-analysis.World journal of surgical oncology · 2022Pooled it
- The role of robotic surgery for the treatment of hilar cholangiocarcinoma: A systematic review.Frontiers in oncology · 2022Pooled it
- The role of neo-adjuvant therapy in cholangiocarcinoma: A systematic review.Frontiers in oncology · 2022Pooled it
- Pooled it
- Current Advances in Minimally Invasive Surgical Management of Perihilar Cholangiocarcinoma.Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract · 2020Pooled it
- Pooled it
- A systematic review of the comparison of the incidence of seeding metastasis between endoscopic biliary drainage and percutaneous transhepatic biliary drainage for resectable malignant biliary obstruction.World journal of surgical oncology · 2019Pooled it
- Best option for preoperative biliary drainage in Klatskin tumor: A systematic review and meta-analysis.Medicine · 2017Pooled it
- Evaluating the performance of multiphasic CT in assessing biliary tumor extent and resectability in perihilar cholangiocarcinoma: insights from a Western population.Abdominal radiology (New York) · 2026Article
- Emerging omics diagnosis of perihilar cholangiocarcinoma.Journal of gastroenterology · 2026Article
- Preoperative biliary drainage in perihilar cholangiocarcinoma: retrospective multicentre analysis.BJS open · 2026Observational
- Role of Endoscopy in Malignant Biliary Obstruction.Diagnostics (Basel, Switzerland) · 2026Review
- Portal vein reconstruction reduces textbook outcome achievement following radical resection for hilar cholangiocarcinoma.Frontiers in oncology · 2026Article
- Article
106 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
An American Hepato-Pancreato-Biliary Association (AHPBA)-sponsored consensus meeting of expert panellists met on 15 January 2014 to review current evidence on the management of hilar cholangiocarcinoma in order to establish practice guidelines and to agree consensus statements. It was established that the treatment of patients with hilar cholangiocarcinoma requires a coordinated, multidisciplinary approach to optimize the chances for both durable survival and effective palliation. An adequate diagnostic and staging work-up includes high-quality cross-sectional imaging; however, pathologic confirmation is not required prior to resection or initiation of a liver transplant trimodal treatment protocol. The ideal treatment for suitable patients with resectable hilar malignancy is resection of the intra- and extrahepatic bile ducts, as well as resection of the involved ipsilateral liver. Preoperative biliary drainage is best achieved with percutaneous transhepatic approaches and may be indicated for patients with cholangitis, malnutrition or hepatic insufficiency. Portal vein embolization is a safe and effective strategy for increasing the future liver remnant (FLR) and is particularly useful for patients with an FLR of <30%. Selected patients with unresectable hilar cholangiocarcinoma should be evaluated for a standard trimodal protocol incorporating external beam and endoluminal radiation therapy, systemic chemotherapy and liver transplantation. Post-resection chemoradiation should be offered to patients who show high-risk features on surgical pathology. Chemoradiation is also recommended for patients with locally advanced, unresectable hilar cancers. For patients with locally recurrent or metastatic hilar cholangiocarcinoma, first-line chemotherapy with gemcitabine and cisplatin is recommended based on multiple Phase II trials and a large randomized controlled trial including a heterogeneous population of patients with biliary cancers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.